Navigation Links
RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer
Date:12/14/2011

Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures. In the past 20 years, numerous treatment regimens have been evaluated for locally-advanced pancreatic cancer with high-dose chemotherapy followed by chemoradiation being the current standard approach. However, the median survival time of these patients remains generally less than 12 months.

Ganitumab is a fully-human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor, (IGF-1R). From preclinical studies, IGF-1R has been shown to play a significant role in tumor cell growth and in tumor cell's resistance to both chemotherapy and radiation treatment. The investigational drug ganitumab is thought to interrupt the process that changes normal cells into cancer, thereby stopping the abnormal growth behavior of a tumor and making it more amenable to chemoradiation treatment.

"Ganitumab is a therapy under investigation that has shown promising results in early-phase trials for patients with metastatic pancreatic cancer," says Christopher Crane, MD, Professor of Radiation Oncology at MD Anderson Cancer Center and principal investigator for the RTOG 1102 trial, Houston, "Collecting information about the best drug dose and safety of administering ganitumab with chemoradiation is critical to further evaluating the efficacy of this treatment regimen for patients with locally-advanced disease," explains Crane.

Up to 42 study participants at institutions across the United States will be enrolled in the trial and will receive 2 months of induction (high-dose) chemotherapy with gemcitabine and ganitumab to provide early systemic treatment and also to select the study participants most likely to benefit from chemoradiation. Previous RTOG studies, such as RTOG 0411, have shown no increase in toxicity during chemoradiation when induction chemotherapy is first administered.

Following induction chemotherapy, study participants will receive ganitumabfirst investigating doses of 12mg/kg and, if tolerated, subsequently 20 mg/kgalong with standard chemoradiation treatment. Upon treatment completion, participants will continue to receive maintenance doses of gemcitabine and ganitumab until tumor progression.

According to Walter Curran, MD, RTOG Group Chair and Executive Director of the Winship Cancer Institute of Emory University in Atlanta, "Amgen is conducting a phase III trial of ganitumab in metastatic pancreatic cancer. If trial results for treatment of metastatic disease are positive, moving forward with a randomized phase II trial for patients with locally advanced disease would be indicated. In this scenario, the RTOG 1102 trial results will expedite further evaluation of this targeted therapy."


'/>"/>
Contact: Nancy Fredericks
nfredericks@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Related medicine news :

1. Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
2. Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
3. Consortium gets $7.2 million contract renewal to promote phase II clinical trials
4. ASU embarks on next phase of an effort to rapidly assess radiation dose
5. Phase II study shows new cancer drug combination significantly delays breast cancer progression
6. First Phase III trial of an alpha-pharmaceutical
7. Osteoporosis Phase III data at 2011 ASBMR Show oral calcitonin tablet is safe and effective
8. Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
9. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
10. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
11. Neurologix presents 1-year data from phase 2 study of NLX-P101 in Parksinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
Breaking Medicine Technology: